What Incyte (INCY) Said on Its Q3 Earnings Call

Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.

MarketBeat • 6 hours ago

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Seeking Alpha • 5 hours ago

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.

Business Wire • 13 hours ago

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.

Zacks Investment Research • 10 hours ago

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • 9 hours ago

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.

Zacks Investment Research • 4 hours ago

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Seeking Alpha • Oct 27, 2026

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”

MarketBeat • Oct 27, 2026

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.

Business Wire • Oct 26, 2026

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Zacks Investment Research • Oct 26, 2026